Cathie Wood
SCNI

Cathie Wood’s Scinai Immunotherapeutics SCNI Stock Holding History

Cathie Wood’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10
Closed -$37K – 296
2021
Q1 		$37K Sell
10
-32
-76% -$140K ﹤0.01% 285
2020
Q4 		$117K Buy
42
+22
+110% +$266K ﹤0.01% 240
2020
Q3 		$776K Buy
+20
New +$768K ﹤0.01% 168

Other funds holding SCNI

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.16B AUM 36.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $49.3B AUM 36.45% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Cathie Wood's SCNI Position: Q2 2021 in Review

Cathie Wood sold out of Scinai Immunotherapeutics (SCNI) in Q2 2021, closing a stake of 10 shares — an estimated $37K sold.

Cathie Wood first reported a position in SCNI in Q3 2020 and held it in 3 quarters. The position peaked at $776K in Q3 2020. 14 funds tracked by Wall St. Rank hold SCNI as of Q2 2021.

  • Cathie Wood reported no remaining Scinai Immunotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Cathie Wood sold 10 Scinai Immunotherapeutics shares in Q2 2021, an estimated $37K.
  • Cathie Wood first reported a position in Scinai Immunotherapeutics in Q3 2020 and held it in 3 quarters.
  • Cathie Wood's Scinai Immunotherapeutics position peaked at $776K in Q3 2020.
  • 14 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2021.

Based on ARK Investment Management's 13F filing for Q2 2021, filed 5 Aug 2021.